VLA1601 + CpG 1018® + 3M-052-AF
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Zika
Conditions
Zika, Zika Virus Infection
Trial Timeline
Mar 25, 2024 → Feb 27, 2026
NCT ID
NCT06334393About VLA1601 + CpG 1018® + 3M-052-AF
VLA1601 + CpG 1018® + 3M-052-AF is a phase 1 stage product being developed by Valneva SE for Zika. The current trial status is completed. This product is registered under clinical trial identifier NCT06334393. Target conditions include Zika, Zika Virus Infection.
Hype Score Breakdown
Clinical
6
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06334393 | Phase 1 | Completed |
Competing Products
5 competing products in Zika
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1893 | Moderna | Phase 1 | 0 |
| mRNA-1325 | Moderna | Phase 1 | 0 |
| mRNA-1893 | Moderna | Phase 2 | 0 |
| VLA1601 + Placebo | Valneva SE | Phase 1 | 23 |
| Zika Virus Immune Globulin (ZIKV-IG) | Emergent BioSolutions | Phase 1 | 19 |